Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combination of DNA Damage, Autophagy, and ERK Inhibition: Novel Evodiamine-Inspired Multi-Action Pt(IV) Prodrugs with High-Efficiency and Low-Toxicity Antitumor Activity
Xiaomeng Liu, Zhe Li, Xinru Xie, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 3, pp. 1852-1872
Closed Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

Nuclear-Targeting Lipid PtIV Prodrug Amphiphile Cooperates with siRNA for Enhanced Cancer Immunochemotherapy by Amplifying Pt-DNA Adducts and Reducing Phosphatidylserine Exposure
Dengshuai Wei, Junning Fan, Jianqin Yan, et al.
Journal of the American Chemical Society (2023) Vol. 146, Iss. 1, pp. 1185-1195
Closed Access | Times Cited: 35
Developing a Ruthenium(III) Complex to Trigger Gasdermin E-Mediated Pyroptosis and an Immune Response Based on Decitabine and Liposomes: Targeting Inhibition of Gastric Tumor Growth and Metastasis
Wenjuan Li, Shanhe Li, Gang Xu, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 18, pp. 13072-13085
Closed Access | Times Cited: 22
Series of Desloratadine Platinum(IV) Hybrids Displaying Potent Antimetastatic Competence by Inhibiting Epithelial–Mesenchymal Transition and Arousing Immune Response
Ming Zhang, Yan Chen, Zhifang Liu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 3, pp. 2031-2048
Closed Access | Times Cited: 13
Exploiting Nanotechnology for Drug Delivery: Advancing the Anti-Cancer Effects of Autophagy-Modulating Compounds in Traditional Chinese Medicine
Zixian Liu, Tianming Lu, Ruoning Qian, et al.
International Journal of Nanomedicine (2024) Vol. Volume 19, pp. 2507-2528
Open Access | Times Cited: 7
Novel NF-κB Inhibitor-Conjugated Pt(IV) Prodrug to Enable Cancer Therapy through ROS/ER Stress and Mitochondrial Dysfunction and Overcome Multidrug Resistance
Meng Wang, Guimei Li, Guiyang Jiang, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 8, pp. 6218-6237
Closed Access | Times Cited: 7
Alendronate PtIV Prodrug Amphiphile for Enhanced Chemotherapy Targeting and Bone Destruction Inhibition in Osteosarcoma
Kaichuang Sun, Lu Yuan, Chen Shen, et al.
Advanced Healthcare Materials (2023) Vol. 13, Iss. 7
Closed Access | Times Cited: 16
Glycyrrhetinic Acid as a Hepatocyte Targeting Ligand-Functionalized Platinum(IV) Complexes for Hepatocellular Carcinoma Therapy and Overcoming Multidrug Resistance
Xiaochao Huang, Guimei Li, Huifang Li, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 10, pp. 8020-8042
Closed Access | Times Cited: 6
Current Status of Novel Multifunctional Targeted Pt(IV) Compounds and Their Reductive Release Properties
Ling‐Wen Xu, Xiangyu Kong, Xinzhi Li, et al.
Molecules (2024) Vol. 29, Iss. 4, pp. 746-746
Open Access | Times Cited: 5
Autophagy-Targeted Platinum(IV) Agents: A New Horizon in Antitumor Drug Development
Suying Li, Yan Chen, Shuaiqi Feng, et al.
Dalton Transactions (2025)
Closed Access
Self-assembled HO-1i-Pt(IV) nanomedicine targeting p38/MAPK and MDR pathways for cancer chemo-immunotherapy
Xiaomeng Liu, Zhe Li, Xiaoya Wang, et al.
Journal of Controlled Release (2025) Vol. 379, pp. 797-813
Closed Access
Discovery of Novel Aromatic Urea-Imidazole Salt Derivatives for Cancer Therapy via Targeting ERK1/2
Mengqi Wang, Shuping Yang, Xinge Li, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Design, Synthesis and Bioactive Evaluation of Topo I/c-MYC Dual Inhibitors to Inhibit Oral Cancer via Regulating the PI3K/AKT/NF-κB Signaling Pathway
Bin Zheng, Yixiao Wang, Ziyan Wu, et al.
Molecules (2025) Vol. 30, Iss. 4, pp. 894-894
Open Access
Discovery of a Novel EF24 Analogue-Conjugated Pt(IV) Complex as Multi-Target Pt(IV) Prodrugs Aims to Enhance Anticancer Activity and Overcome Cisplatin Resistance
Meng Wang, Guimei Li, Nan Xu, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Maintaining calcium homeostasis as a strategy to alleviate nephrotoxicity caused by evodiamine
Chun-qi Yang, Cheng-Cai Lai, Jin-Chao Pan, et al.
Ecotoxicology and Environmental Safety (2024) Vol. 281, pp. 116563-116563
Open Access | Times Cited: 4
Evodiamine encapsulated by hyaluronic acid modified zeolitic imidazolate framework-8 for tumor targeted therapy
Qiang Zhou, Dandan Xie, Kui Wang, et al.
Drug Delivery and Translational Research (2024)
Closed Access | Times Cited: 3
NIR Light and GSH Dual-Responsive Upconversion Nanoparticles Loaded with Multifunctional Platinum(IV) Prodrug and RGD Peptide for Precise Cancer Therapy
Xiaomeng Liu, Zhenzhen Zhu, Xinrui He, et al.
ACS Applied Materials & Interfaces (2024) Vol. 16, Iss. 31, pp. 40753-40766
Closed Access | Times Cited: 3
PROTAC derivatization of natural products for target identification and drug discovery: Design of evodiamine-based PROTACs as novel REXO4 degraders
Shuqiang Chen, Kaijian Bi, Huixin Liang, et al.
Journal of Advanced Research (2023) Vol. 63, pp. 219-230
Open Access | Times Cited: 9
Dual-targeting tumor cells hybrids derived from Pt(IV) species and NF-κB inhibitors enables cancer therapy through mitochondrial dysfunction and ER stress and overcomes cisplatin resistance
Meng Wang, Guimei Li, Guiyang Jiang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 266, pp. 116095-116095
Closed Access | Times Cited: 9
Disruption of lipid metabolism to induce ferroptosis using multifunctional fibrate-Pt(iv) prodrugs for cancer treatment
Peng Sun, Jia-Qian Wang, Qiang Xie, et al.
Inorganic Chemistry Frontiers (2024) Vol. 11, Iss. 10, pp. 2914-2931
Closed Access | Times Cited: 2
Structure-Guided Discovery and Preclinical Assessment of Novel (Thiophen-3-yl)aminopyrimidine Derivatives as Potent ERK1/2 Inhibitors
Shuai Wen, Huan Xiao, Panpan Yang, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 8, pp. 6425-6455
Closed Access | Times Cited: 2
Hydroxychloroquine Platinum(IV) Conjugate Displaying Potent Antimetastatic Activities by Suppressing Autophagy to Improve the Tumor Microenvironment
Linming Li, Yan Chen, Ming Zhang, et al.
Dalton Transactions (2024) Vol. 53, Iss. 33, pp. 13890-13905
Closed Access | Times Cited: 2
Ligustrazine-Derived Chalcones-Modified Platinum(IV) Complexes Intervene in Cisplatin Resistance in Pancreatic Cancer through Ferroptosis and Apoptosis
Meng Wang, Guoxiu Cao, Junjie Zhou, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 19, pp. 13587-13606
Closed Access | Times Cited: 7
Novel Platinum(IV) complexes intervene oxaliplatin resistance in colon cancer via inducing ferroptosis and apoptosis
Zhikun Liu, Jinyuan Cai, Guiyang Jiang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 263, pp. 115968-115968
Closed Access | Times Cited: 7
Gemfibrozil-Platinum(IV) Precursors for New Enhanced-Starvation and Chemotherapy In Vitro and In Vivo
Xueqing Song, Xu Guo, Yixin Ding, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 9, pp. 7033-7047
Closed Access | Times Cited: 1
Design of Evodiamine–Glucose Conjugates with Improved In Vivo Antitumor Activity
Zhe Wu, Shuqiang Chen, Zhipeng Chen, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 9, pp. 7373-7384
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top